Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript [Seeking Alpha]